Patients with overactive bladder who have not responded to medication now have a small implant near the ankle, activated daily by a removable external wearable, as an alternative to the larger sacral nerve implants that have dominated the category for two decades. BlueWind Medical, the company behind the Revi System (the only FDA-cleared implantable tibial neuromodulation device for urgency urinary incontinence), closed $47.8 million in combined equity and debt financing on 14 May 2026 to scale its US commercial rollout. The round is the second meaningful capital event in the implantable tibial neuromodulation category in eight months, following Medtronic’s FDA approval of its competing Altaviva device in September 2025.

The round

BlueWind raised the $47.8 million from new and existing institutional healthcare investors as a combination of equity and debt. The company has not publicly named a lead investor in the syndicate. Proceeds will fund continued expansion of the US commercial sales organisation and market-access work to broaden insurance coverage and provider adoption of Revi. The round is the largest capital milestone in the implantable tibial neuromodulation category to date.

What Revi does

Revi is implanted near the ankle in a single outpatient procedure under local anaesthesia. The small implant sits adjacent to the posterior tibial nerve, the peripheral nerve that carries the signals controlling bladder function. Patients activate the implant at home by wearing a lightweight external wearable for short sessions; the wearable transmits power and signal to the implant, which then delivers targeted electrical stimulation to the tibial nerve.

The approach contrasts with two established neuromodulation pathways for urgency urinary incontinence. Sacral neuromodulation (Medtronic InterStim, and the Axonics R20 product line that Boston Scientific acquired in November 2024 as part of a $3.7 billion equity-value deal) implants a larger pulse generator in the upper buttock with a lead running to the sacral nerve roots near the spine. Percutaneous tibial nerve stimulation (PTNS) delivers similar tibial-nerve stimulation but requires in-office sessions with a needle electrode, with no implantable component. Revi keeps the tibial-nerve target but replaces the in-office sessions with an at-home wearable activating a permanent implant.

OASIS clinical data

BlueWind has now reported three-year follow-up data from its pivotal OASIS trial, published in the Journal of Urology. The trial supported the original FDA clearance and the 36-month data reinforced the durability case: sustained reduction in urgency urinary incontinence episodes, a favourable safety profile, and 95% patient satisfaction at three years. The two-year readout was published earlier in the same journal. The combination of long-term efficacy data, a smaller and less invasive surgical footprint than sacral neuromodulation, and an at-home activation pattern that does not require repeat in-office visits is the commercial wedge BlueWind is now scaling against.

The category split from sacral nerve stimulation

Implantable tibial neuromodulation now has two FDA-cleared options. Medtronic’s Altaviva, approved in September 2025, is the second entrant after Revi. Medtronic positions Altaviva inside a portfolio that already includes InterStim sacral neuromodulation; the company has highlighted Altaviva’s 15-year battery and same-day therapy activation as differentiators. BlueWind is the focused single-product company in the category. The competitive question for the next 12-18 months is whether implantable tibial neuromodulation is a true alternative to sacral neuromodulation (with patients and physicians choosing between the two anatomical targets) or a complementary first-line therapy that captures patients before they progress to sacral implantation.

Reimbursement is the other variable. Sacral neuromodulation has well-established coding and coverage. Tibial neuromodulation reimbursement is still building out as commercial volume grows. The CPT codes and Medicare coverage decisions for the next twelve months will set the speed at which Revi and Altaviva can scale to revenue parity with the sacral category.

What to watch

The next BlueWind-specific signal is the company’s implants-to-date count and any disclosed FY26 revenue trajectory, which the company has not released publicly as a private entity. The peer signal is the Medtronic Q4 FY26 earnings call (today, 20 May 2026), which is expected to include the first quarterly commentary on Altaviva commercial performance. If Medtronic discloses meaningful early Altaviva uptake, the implantable tibial neuromodulation category is consolidating faster than expected; if Altaviva is slow out of the gate, BlueWind has more runway as the first mover.

The broader bioelectronic-medicine commercial inflection Inside BCI tracked on 5 May continues to extend across indications. Heart failure (CVRx Barostim, Humana coverage win 16 May), epilepsy (NeuroPace Q1 and NAUTILUS data 18 May), and now overactive bladder are all moving on parallel tracks. The pattern is consistent: implantable, closed-loop or sensor-paired devices, building reimbursement coverage ahead of full clinical readouts.

Sources

• BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi System (BusinessWire, 14 May 2026)
• BlueWind Medical raises $47.8M to support Revi commercialization (MassDevice)
• BlueWind Medical Raises $47.8M in Equity and Debt (FinSMEs)
• BlueWind Medical Lands $47.8M to Scale ‘Smart Ankle’ UUI Therapy (BriefGlance)
• Medtronic wins FDA approval for urinary incontinence device (MedTech Dive, September 2025)
• Altaviva System product page (Medtronic)
• Boston Scientific Closes Acquisition of Axonics (PR Newswire, 15 November 2024)